General

RegeneRx Biopharmaceuticals, Inc. (the “Company”, “We”, “Us”, “Our”), is a biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, we are developing Thymosin beta 4 (“Tß4 ” ), a 43 amino acid peptide. Current research suggests that Tß4 may prove efficacious for multiple medical indications, therefore we are developing several Tß4-based therapeutic products. We hold over fifty world-wide patents and patent applications related to dermal, ophthalmic, and internal wounds and tissue repair, cardiac and neurological...